Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
PaxMedica Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
PXMD
Over the counter
8731
https://www.paxmedica.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for PaxMedica Inc
PaxMedica Secures Immediate Exercise of Warrants
- Sep 3rd, 2024 12:00 pm
PaxMedica Reports First Patient Treated with PAX-101 for Fatal African Sleeping Sickness Infection
- Aug 27th, 2024 12:00 pm
PaxMedica Files Nasdaq Delisting Appeal Notice and Prepares for Upcoming FDA Meeting on PAX-101
- May 15th, 2024 12:30 pm
PaxMedica Provides Company Update and Continues to Advance PAX-101 Regulatory Strategy
- May 7th, 2024 12:30 pm
PaxMedica's CEO and Malawi Health Official Discuss Urgent Medical Crisis in Bell2Bell Podcast
- Apr 26th, 2024 12:30 pm
PaxMedica Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101
- Apr 23rd, 2024 12:30 pm
PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness
- Apr 16th, 2024 8:30 pm
PaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA Submission
- Apr 11th, 2024 8:30 pm
PaxMedica Updated Company Presentation Highlighting Innovations in Autism Spectrum Disorder Treatments
- Mar 13th, 2024 12:20 pm
IBN Highlights PaxMedica's Video Release on Transformative ASD Study
- Jan 18th, 2024 1:30 pm
PaxMedica on Promising Path to Address Unmet ASD Needs
- Jan 17th, 2024 1:30 pm
PaxMedica Files 8-K Following Nasdaq Compliance Achievement
- Dec 22nd, 2023 7:00 pm
PaxMedica CEO Howard Weisman Sheds Light on Achievements for ASD Therapy Pipeline
- Dec 19th, 2023 2:30 pm
PaxMedica Inc. Covered in H.C. Wainwright & Co. Research Report
- Dec 12th, 2023 2:00 pm
PaxMedica CEO Featured in Just-Released Fireside Chat Video
- Dec 8th, 2023 1:30 pm
PaxMedica Closes Public Offering of Approximately $7M, Continues Pursuing ASD Pipeline
- Dec 7th, 2023 2:00 pm
PaxMedica Releases Fireside Chat Video with CEO Howard Weisman
- Dec 6th, 2023 1:00 pm
PaxMedica Closes on Public Offering Reaching Estimated $7M
- Dec 1st, 2023 6:30 pm
PaxMedica Announces Closing of $7.0 Million Public Offering
- Nov 22nd, 2023 9:10 pm
PaxMedica Announces Pricing of $7M Public Offering
- Nov 22nd, 2023 1:30 pm
Scroll